We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

TECAN GROUP LTD.

Tecan is a provider of automated laboratory instruments and solutions for people working in clinical diagnostics, bas... read more Featured Products: More products

Download Mobile App




Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays

By LabMedica International staff writers
Posted on 04 Apr 2025
Print article
Image: The Procollagen-III-peptide (PIIINP) ELISA kit (Photo courtesy of Cisbio Bioassays)
Image: The Procollagen-III-peptide (PIIINP) ELISA kit (Photo courtesy of Cisbio Bioassays)

Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the global life sciences and diagnostics company, Revvity Inc. (Waltham, MA, USA). The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits.

The asset purchase relates to the following ELISA kits - CGA-ELISA-NG (Chromogranin A New Gen. ELISA) – CE IVD that aids diagnosis by determining the presence and progression of neuroendocrine tumor, in adults; P3NP-ELISA (N-Terminal Procollagen III Peptide ELISA) – CE IVD that measures the levels of PIIINP in serum, EDTA or Heparin plasma to assess collagen III synthesis and monitor the risk of liver fibrosis in psoriasis patients receiving methotrexate; and CGA-EL-US-NG RUO and P3NP-EL-US RUO which are research use only products for supporting further scientific advancements in research activities.

To ensure uninterrupted availability of these four ELISA kits until completion of the asset transfer, IBL International GmbH, a Tecan company, has signed a Master Distributorship Agreement with Cisbio Bioassays to resell the kits. IBL has a proven track record of delivering reliable and precise specialty diagnostic tools, including high-quality IVD products. Upon completion of the asset transfer, IBL will assume full responsibility for the manufacturing, distribution and regulatory compliance of the kits. Bringing these products into the Tecan Group will ensure their continued availability to users while upholding the highest quality and regulatory standards.

“This strategic purchase aligns with our commitment to supporting customers with high-quality solutions while strengthening our portfolio in specialty diagnostics," said Mukta Acharya, Head of Tecan’s Life Sciences Business. "As regulatory requirements continue to evolve, we are proactively expanding our offering to ensure laboratories have access to reliable, compliant solutions that meet their needs today and in the future. Tecan and Cisbio have a long-standing collaboration in the IVD sector. The transition of these important ELISA kits marks a strategic step to expand the IBL specialty diagnostics portfolio under IVDR.”

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.